Clincal Outcomes Ans Assessment Of Quality of Life of Patients Diagnosed With Metastatic Renal Cell Carcinoma and Treated With Sunitinib at the Nairobi Max Access Solutions Clinic
Abstract
Background.
Sunitinib Was Approved in 2006 as Standard Therapy for Metastatic Renal Cell Carcinoma..............................
Publisher
University of Nairobi
Rights
Attribution-NonCommercial-NoDerivs 3.0 United StatesUsage Rights
http://creativecommons.org/licenses/by-nc-nd/3.0/us/Collections
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States